Insider Trading Alert - HTGC, OREX And TEP Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 15, 2014, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $750.00 to $8,750,000.00.

Highlighted Stocks Traded by Insiders:

Hercules Technology Growth Capital (HTGC) - FREE Research Report

Henriquez Manuel A, who is President & CEO at Hercules Technology Growth Capital, sold 50,000 shares at $15.40 on Sept. 15, 2014. Following this transaction, the President & CEO owned 1.9 million shares meaning that the stake was reduced by 2.63% with the 50,000-share transaction.

The shares most recently traded at $15.06, down $0.34, or 2.25% since the insider transaction. Historical insider transactions for Hercules Technology Growth Capital go as follows:

  • 4-Week # shares sold: 124,000
  • 12-Week # shares bought: 3,127
  • 12-Week # shares sold: 171,000
  • 24-Week # shares bought: 3,127
  • 24-Week # shares sold: 339,733

The average volume for Hercules Technology Growth Capital has been 550,100 shares per day over the past 30 days. Hercules Technology Growth Capital has a market cap of $972.8 million and is part of the financial sector and real estate industry. Shares are down 8.41% year-to-date as of the close of trading on Monday.

Hercules Technology Growth Capital, Inc. is a private equity, venture capital, and venture debt firm specializing in providing capital to privately held venture capital and private equity backed companies and select publicly-traded companies. The stock currently has a dividend yield of 8.06%. The company has a P/E ratio of 9.3. Currently, there are 4 analysts who rate Hercules Technology Growth Capital a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HTGC - FREE

TheStreet Quant Ratings rates Hercules Technology Growth Capital as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Hercules Technology Growth Capital Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Orexigen Therapeutics (OREX) - FREE Research Report

Narachi Michael, who is President and CEO at Orexigen Therapeutics, bought 50,000 shares at $4.78 on Sept. 15, 2014. Following this transaction, the President and CEO owned 58,026 shares meaning that the stake was boosted by 622.98% with the 50,000-share transaction.

Hagan Joseph P, who is Sr. VP, Corporate Development at Orexigen Therapeutics, bought 5,000 shares at $4.69 on Sept. 15, 2014. Following this transaction, the Sr. VP, Corporate Development owned 13,026 shares meaning that the stake was boosted by 62.3% with the 5,000-share transaction.

The shares most recently traded at $4.86, up $0.17, or 3.5% since the insider transaction.

The average volume for Orexigen Therapeutics has been 3.5 million shares per day over the past 30 days. Orexigen Therapeutics has a market cap of $632.3 million and is part of the health care sector and drugs industry. Shares are down 13.32% year-to-date as of the close of trading on Monday.

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Currently, there are 5 analysts who rate Orexigen Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OREX - FREE

TheStreet Quant Ratings rates Orexigen Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, disappointing return on equity, weak operating cash flow, generally high debt management risk and generally disappointing historical performance in the stock itself. Get the full Orexigen Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Tallgrass Energy Partners (TEP) - FREE Research Report

Brauchle Gary J, who is See Remarks at Tallgrass Energy Partners, bought 570 shares at $44.60 on Sept. 15, 2014. Following this transaction, the See Remarks owned 58,388 shares meaning that the stake was boosted by 0.99% with the 570-share transaction.

Cook Roy Nolan, who is Director at Tallgrass Energy Partners, bought 5,000 shares at $44.50 on Sept. 15, 2014. Following this transaction, the Director owned 33,000 shares meaning that the stake was boosted by 17.86% with the 5,000-share transaction.

The shares most recently traded at $44.73, up $0.23, or 0.51% since the insider transaction. Historical insider transactions for Tallgrass Energy Partners go as follows:

  • 4-Week # shares bought: 5,735
  • 12-Week # shares bought: 5,735
  • 24-Week # shares bought: 5,735

The average volume for Tallgrass Energy Partners has been 281,500 shares per day over the past 30 days. Tallgrass Energy Partners has a market cap of $1.5 billion and is part of the basic materials sector and energy industry. Shares are up 69.38% year-to-date as of the close of trading on Monday.

Tallgrass Energy Partners, LP acquires, owns, develops, and operates various midstream energy assets in North America. The company operates in two segments, Gas Transportation and Storage, and Processing. The stock currently has a dividend yield of 3.43%. The company has a P/E ratio of 37.6. Currently, there are 5 analysts who rate Tallgrass Energy Partners a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TEP - FREE

TheStreet Quant Ratings rates Tallgrass Energy Partners as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins. Get the full Tallgrass Energy Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Tesla Slumps After Mary McCormack Tweets Husband's Flaming Model S

Tesla Slumps After Mary McCormack Tweets Husband's Flaming Model S

Stocks Dive Globally as U.S.-China Trade War Intensifies

Stocks Dive Globally as U.S.-China Trade War Intensifies

China Trade War, Google, JD.com, Tesla, Brooks Koepka - 5 Things You Must Know

China Trade War, Google, JD.com, Tesla, Brooks Koepka - 5 Things You Must Know

Google Invests $550 Million in JD.com and 4 Other Stories to Watch Monday

Google Invests $550 Million in JD.com and 4 Other Stories to Watch Monday

Global Oil Prices Mixed as OPEC Production Talks, China Tariffs Weigh on Markets

Global Oil Prices Mixed as OPEC Production Talks, China Tariffs Weigh on Markets